Safety surveillance is the most important aspect for post-marketing research of Chinese medicine. However, passive monitoring systems or phase four clinical trials or large sample epidemiology studies were historically the common ways of surveillance of post-marketing Chinese medicine. However those studies can no longer meet the expectations, and there are many more evidence sources for post-marketing Chinese medicine safety evaluation, eg. active surveillance from observational cohort study and study on hospital information system. These data and study can provide adequate source data for post-marketing Chinese medicine research. The most prominent problem is how to integrate different evidences from multiple sources. This article suggests we should build an evidence-based system to evaluate post-marketing Chinese medicines safety.